An investigation on behalf of investors in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares over potential wrongdoing at Tetraphase Pharmaceuticals was announced and NASDAQ:TTPH stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 01/19/2016 --An investigation for shareholders in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was announced over potential breaches of fiduciary duties by certain directors at Tetraphase Pharmaceuticals.

Investors who purchased shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) and currently hold any of those NASDAQ:TTPH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

On September 8, 2015, Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin. Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) declined to as low as $7.20 per share on October 1, 2015.

On January 15, 2016, NASDAQ:TTPH shares closed at $5.69 per share.

Those who purchased shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com